Trending NewsTrending NewsNASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis $25.83 +0.51 (+2.01%) As of 08/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RARE alerts:Sign Up Key Stats Today's Range$25.69▼$26.7550-Day Range$24.85▼$35.8752-Week Range$18.29▼$39.89Volume2.39 million shsAverage Volume2.11 million shsMarket Capitalization$2.55 billionP/E RatioN/ADividend YieldN/APrice Target$58.89Consensus RatingModerate Buy Company Overview Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval. The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders. These products illustrate Ultragenyx’s approach of targeting well-defined genetic defects with therapies designed to correct or mitigate the underlying cause of disease. Ultragenyx maintains a robust clinical pipeline, with investigational treatments in various stages of development for conditions such as congenital hyperinsulinism, pyruvate kinase deficiency and other rare enzymatic or metabolic disorders. Ultragenyx operates globally, with a commercial presence in the United States, Europe and Canada, and research collaborations spanning multiple continents. The company works closely with patient advocacy groups and academic centers to support clinical trials and foster patient access. Under the leadership of founder and Chief Executive Officer Emil Kakkis—an experienced clinician-scientist in the rare disease field—Ultragenyx continues to expand its capabilities in manufacturing, regulatory affairs and global commercialization to deliver transformative therapies for underserved patient populations.AI Generated. May Contain Errors. Read More Ultragenyx Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreRARE MarketRank™: Ultragenyx Pharmaceutical scored higher than 69% of companies evaluated by MarketBeat, and ranked 230th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.84, and is based on 1 strong buy rating, 15 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialUltragenyx Pharmaceutical has a consensus price target of $58.89, representing about 128.0% upside from its current price of $25.83.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ultragenyx Pharmaceutical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($4.03) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ultragenyx Pharmaceutical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.01% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 8.28.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 11.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.04 News SentimentUltragenyx Pharmaceutical has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 32 news articles for Ultragenyx Pharmaceutical this week, compared to 10 articles on an average week.Search InterestOnly 4 people have searched for RARE on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows5 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $207,455.00 in company stock.Percentage Held by Insiders5.20% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ultragenyx Pharmaceutical's insider trading history. Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RARE Stock News HeadlinesCantor Fitzgerald Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)August 23 at 10:00 AM | theglobeandmail.comWedbush Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)August 23 at 10:00 AM | theglobeandmail.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.August 23 at 1:00 AM | Profits Run (Ad)Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst SaysAugust 23 at 1:48 AM | americanbankingnews.comWells Fargo & Company Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) StockAugust 22 at 4:35 AM | americanbankingnews.comCantor Fitzgerald Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $103.00August 22 at 2:58 AM | americanbankingnews.comCitigroup Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00August 22 at 2:24 AM | americanbankingnews.comUltragenyx: Progress Is Real, But Profitability Is The Real Test (Rating Upgrade)August 21 at 12:27 PM | seekingalpha.comSee More Headlines RARE Stock Analysis - Frequently Asked Questions How have RARE shares performed this year? Ultragenyx Pharmaceutical's stock was trading at $23.00 at the beginning of 2026. Since then, RARE stock has increased by 12.3% and is now trading at $25.83. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) issued its quarterly earnings results on Tuesday, August, 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical's quarterly revenue was up 28.5% compared to the same quarter last year. Read the conference call transcript. When did Ultragenyx Pharmaceutical IPO? Ultragenyx Pharmaceutical (RARE) raised $112 million in an IPO on Friday, January 31st 2014. The company issued 5,760,369 shares at a price of $19.00-$20.00 per share. Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's top institutional shareholders include BlackRock Inc. (10.82%), Wellington Management Group LLP (1.27%), Bank of America Corp DE (1.16%) and Jefferies Financial Group Inc. (0.94%). Insiders that own company stock include Emil D Kakkis, Thomas Richard Kassberg, Eric Crombez, John Richard Pinion, Howard Horn, Karah Herdman Parschauer, Erik Harris, Theodore Alan Huizenga, Shehnaaz Suliman, Corazon (Corsee) D Sanders and Matthew K Fust. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/04/2026Today8/23/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 RARE's financial health is in the Yellow zone, according to TradeSmith. RARE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RARE CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,371Year Founded2010Price Target and Rating Average Price Target for Ultragenyx Pharmaceutical$58.89 High Price Target$103.00 Low Price Target$25.00 Potential Upside/Downside+128.0%Consensus RatingModerate Buy Rating Score (0-4)2.84 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($5.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$575 million Net Margins-81.79% Pretax Margin-81.18% Return on Equity-1,024.42% Return on Assets-44.40% Debt Debt-to-Equity RatioN/A Current Ratio1.73 Quick Ratio1.56 Sales & Book Value Annual Sales$673 million Price / Sales3.78 Cash FlowN/A Price / Cash FlowN/A Book Value($2.95) per share Price / Book-8.76Miscellaneous Outstanding Shares98,590,000Free Float93,462,000Market Cap$2.55 billion OptionableOptionable Beta0.35 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:RARE) was last updated on 8/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
